Osimertinib-Induced Cardiomyopathy
Shruti Patel, Sherry‐Ann Brown, Jilan Kubusek, Aaron S. Mansfield, Narjust Duma
Abstract
Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.)
Topics & Concepts
OsimertinibCardiotoxicityMedicineExacerbationCardiomyopathyInternal medicineLung cancerHeart failureEpidermal growth factor receptorCardiologyOncologyErlotinibCancerChemotherapyLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer